CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Exe
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-05 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders. Dear Shareholders, With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead
Biotechnology, Pharmaceuticals
2026-01-02 8:00 AM EST | PharmaTher Holdings Ltd.
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-31 5:00 PM EST | TempraMed Technologies Ltd
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceed
Biotechnology, Pharmaceuticals, Health
2025-12-31 2:38 PM EST | Hemostemix Inc.
Telescope Grants Stock Options, RSUs and Settles Debt with Shares
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries announces that it has authorized the grant of incentive stock options (the "Options"), restricted share units (the "RSUs") as well as the issuance of common shares to settle outstanding fees owed to its
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-31 8:00 AM EST | Telescope Innovations Corp.
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-29 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The Company generated revenues of $5.8 million during this period, with an Adjusted EBITDA loss of $402K (Figure 1). Telescope continues
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-23 8:00 PM EST | Telescope Innovations Corp.
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-23 4:40 PM EST | Theralase Technologies Inc.
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physic
Biotechnology, Pharmaceuticals, Health
2025-12-23 9:10 AM EST | Hemostemix Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighte
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-22 7:00 AM EST | Cannabis Bioscience International Holdings
Herbal Dispatch CEO Philip Campbell Weighs in on Global Implications of USA Cannabis Reclassification to Schedule III
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") a leading Canadian cannabis e-commerce platform specializing in small-batch craft cannabis, today shared insights from CEO Philip Campbell regarding President Trump's landmark decision to shift cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act. "This development stands a
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-12-19 9:51 AM EST | Herbal Dispatch Inc.
Maxwell Biosciences Subsidiary Havih Announces Partnership with the Government of Andhra Pradesh
Austin, Texas--(Newsfile Corp. - December 18, 2025) - Maxwell Biosciences subsidiary, Havih Envirosciences, an Indian citizen-owned and operated life sciences company, announced a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities in the state. The collaboration was formalized through an agreement with the Andhra Pradesh Centre for Advanced Research on Livestock Limited (APCARL) on November 21, 2025.
Biotechnology, Pharmaceuticals
2025-12-18 9:00 AM EST | Maxwell Biosciences, Inc.
BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence
Biotechnology, Pharmaceuticals, Health
2025-12-18 7:30 AM EST | BioHarvest Sciences Inc.
Optimi Health Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-18 7:00 AM EST | Optimi Health Corp.
InMed Announces Results of 2025 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders held on December 17, 2025 (the "Meeting"), the matters put forward before shareholders for consideration and ap
Biotechnology, Pharmaceuticals
2025-12-17 8:00 PM EST | InMed Pharmaceuticals
TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
Highlights: Manufacturing site in Florida expands TempraMed's U.S. production footprint Increases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturers Shortens delivery timelines and improves service for customers in the United States where majority of devices have been sold to date Reduces COGS through localized production, improved logistics
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-17 5:00 PM EST | TempraMed Technologies Ltd
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accor
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-17 4:19 PM EST | NervGen Pharma Corp.